In the phase III FLAURA trial, 556 untreated advanced NSCLC patients with EGFR mutation were randomly assigned to osimertinib versus standard of care (SOC) EGFR TKI (gefitinib or erlotinib). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.